UK-based pharmaceutical company ViiV Healthcare has initiated its Phase III programme to support the regulatory filings of a two-drug regimen of dolutegravir (Tivicay) and lamivudine (Epivir) to treat HIV-1 infection in adults.

Dolutegravir (Tivicay) is developed as an integrase strand transfer inhibitor (INSTI) to be used in combination with other anti-retroviral agents indicated to treat HIV.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The replication of HIV is blocked by the integrase inhibitors by preventing the viral DNA from adhering into the genetic material of human immune cells (T-cells).

Lamivudine is a nucleoside analogue used in combination with other anti-retroviral agents to treat HIV infection. It is available in branded (Epivir) and other generic forms.

"We believe the clinical profile for dolutegravir presents an important opportunity to investigate the possibility of first-line treatment of HIV with a two-drug regimen."

ViiV’s Phase III programme is comprised of two identical studies, GEMINI I and II.

Both the studies are randomised, double-blind trials designed to evaluate the safety, efficacy, and tolerability of a two-drug regimen of dolutegravir and lamivudine against dolutegravir and two nucleoside reverse transcriptase inhibitors administered on a once-daily basis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The studies are expected to enrol about 700 HIV patients each who have not received any prior anti-retroviral therapy.

The patients will be randomised on a 1:1 basis to be administered with dolutegravir and lamivudine or dolutegravir and tenofovir / emtricitabine fixed-dose combination.

The studies are primarily focused to measure the efficacy of dolutegravir and lamivudine, which will be tested after completing 48 weeks of the study and thereafter continue determining its anti-viral activity, tolerability and safety through Week 148.

ViiV healthcare chief scientific and medical officer John Pottage said: “We believe the clinical profile for dolutegravir presents an important opportunity to investigate the possibility of first-line treatment of HIV with a two-drug regimen.

“With this ambitious phase III programme, we will explore whether this two-drug regimen can fundamentally change the existing HIV treatment strategy, reducing the number of medications and potentially streamlining treatment regimens for people living with HIV.”

ViiV is conducting the Gemini trials as its third development programme aimed at treating HIV.